Publication | Closed Access

Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors

VaccinationProtective Immune ResponseImmunologyTumor ImmunityTherapeutic VaccineImmunotherapeuticsNovel CombinationsSoluble Protein AntigenVaccine DesignImmunotherapyMedicineRadiation OncologyTumor Microenvironment